NCT03126643Approved For Marketing不适用
Expanded Access to Nivolumab (Opdivo)
Bristol-Myers Squibb0 个研究点开始时间: 2017年4月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
研究概览
简要总结
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk.
When contacted by a treating physician, BMS will consider requests for providing early patient access to Nivolumab in pediatric patients exhibiting a high mutational load.
详细描述
Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join an early patient access program.
To learn more about early patient access programs, your doctor may contact BMS using the information provided below.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- — 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access to Elotuzumab (Empliciti) for Multiple MyelomaMultiple MyelomaNCT03126617Bristol-Myers Squibb
No Longer Available
不适用
Individual Patient Expanded Access-Glembatumumab VedotinMetastatic gpNMB Expressing Triple Negative Breast CancerNCT03067935Celldex Therapeutics
已完成
2 期
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract CancersBiliary Tract CancerBiliary Tract NeoplasmsNCT02829918H. Lee Moffitt Cancer Center and Research Institute54
No Longer Available
不适用
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaMalignant MelanomaNCT02186249Bristol-Myers Squibb
No Longer Available
不适用
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung CancerNCT02475382Bristol-Myers Squibb